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Abstract

The purpose of this literature review is to explore metformin’s role in the treatment of patients
with prediabetes within the primary care setting. The efficacy of metformin versus lifestyle
modifications will be compared as well as metformin, as adjunctive therapy, to lifestyle
modifications. Along with efficacy, a systematic analysis will examine the three abovementioned therapies regarding diabetes risk reduction. Lastly, this review will examine the safety
and tolerability of metformin, specifically in patients with prediabetes. The data presented shows
evidence that lifestyle modifications are first-line treatment for prediabetes while metformin use
should be reserved for those who fail lifestyle modifications or are considered to be high-risk
and/or patients that have shown more efficacious results with metformin therapy: BMI ≥ 35
kg/m2, patients less than 60 years old, and women who have a prior history of gestational
diabetes mellitus. Decades of research show that metformin is an effective and safe treatment
option for patients with prediabetes. However, the combined efficacy of lifestyle modifications
and metformin use for prediabetes needs to be further studied to find out why additive benefits
are not demonstrated.
Keywords: prediabetes, metformin in prediabetes, lifestyle modifications and prediabetes, and
prevention of diabetes.
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Introduction

Prediabetes affects approximately one in three adults, 84 million people, in the United
States (CDC, 2019). Lifestyle modifications, consisting of diet and exercise, have been the
longstanding initial treatment in patients diagnosed with prediabetes. Lifestyle interventions
alone often prove difficult for patients to sustain, and weight shed can be regained. Metformin is
a well-established drug that has demonstrated its effectiveness in decreasing A1C levels in
patients with diabetes for decades. The purpose of this study is to reveal the most effective
treatment plan for patients who are diagnosed with prediabetes, to avoid disease progression to
type II diabetes mellitus.
Statement of the Problem
The American Diabetes Association has given an “A” recommendation for the use of
Metformin to be considered in prediabetic patients (Standards of Medical Care in Diabetes,
2018). Prediabetic patient populations, who might especially benefit from the use of Metformin,
include patients with a BMI ≥ 35 kg/m2, patients less than 60 years old, and women who have a
prior history of gestational diabetes mellitus (Standards of Medical Care in Diabetes, 2018).
Unfortunately, less than 1 percent of prediabetic patients are prescribed Metformin (Tseng, Yeh,
& Maruthur, 2017). Most providers advise his or her patients to initiate treatment of prediabetes
with lifestyle modifications first. However, lifestyle modifications may not be enough to combat
prediabetes progression to diabetes—a diagnosis that is associated with microvascular and
macrovascular complications. Therefore, primary care providers must be educated on the latest
recommended guidelines to decipher the efficacy of treatment options in prediabetic patients.
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Research Questions
This literature review addresses metformin’s role in the treatment of patients with
prediabetes (having a hemoglobin A1C level between 5.7-6.4%, fasting plasma glucose (FPG) of
100-125 mg/dL, or oral glucose tolerance test (OGTT) between 140-199 mg/dL). Efficacy of
metformin versus lifestyle modifications is compared as well as metformin, as adjunctive
therapy, to lifestyle modifications. A systematic analysis will examine the efficacy of the three
therapies, as mentioned above, regarding diabetes risk reduction. It will also examine the safety
and tolerability of metformin for patients with prediabetes.
Research Methods
In determining the foundation of this article, Clinical Key, Medline, Cochrane, PubMed,
Science Direct were searched, and articles regarding lifestyle modifications versus metformin for
diabetes prevention and lifestyle modifications plus metformin use in patients with prediabetes
were chosen. The search included key phrases, terms, and MesH terms including prediabetes,
metformin in prediabetes, lifestyle modifications and prediabetes, and prevention of diabetes.
The original search included research from the past four years (2017-2020). However, the search
was expanded to the past twenty-one years (1999-2020) due to needing to include one of the
preliminary research studies of metformin for the use of prediabetes. A filter was added to
include only peer-reviewed journal articles. The focus of this literature review is to determine
whether metformin use in prediabetes is efficacious and reduces the risk of progression to
diabetes.
Literature Review
Upon reviewing the literature, it is evident that the use of Metformin, the use of lifestyle
modifications, and the combined effects of Metformin and lifestyle modifications in patients with
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prediabetes have been thoroughly studied. Most primary care providers initiate lifestyle
modifications in patients with prediabetes. However, Metformin may be more efficacious in
some or all patient populations with prediabetes.
Patterns of Diabetes Screening and the Prevalence of Metformin Use for Prediabetes
The goal of this survey conducted by Shealy et al. (2019) via using data from the
National Ambulatory Medical Care Survey (NAMCS), was to assess the prevalence of screening
for diabetes and treatment of prediabetes according to published diabetes guidelines.
The study sample consisted of combining NAMCS survey data from the years 20122015. Each patient visit was tracked—specifically, lab tests and screenings that were recorded
annually. The data was then filtered to include only participants that met the American Diabetes
Association’s criteria for screening of asymptomatic adults for prediabetes/diabetes. This
specifically included: adults 45 years and older and adults between the ages of 18-44 who had a
body mass index (BMI) of 25 or higher and also had at least one of the subsequent risk factors:
“African American, Hispanic, Asian, Pacific Island, Native American, hypertension, CVD,
PCOS, or abnormal high-density lipoprotein (HDL, less than or equal to 35 mg/dL) or
triglyceride (TG, greater than or equal to 250 mg/dL) levels” (Shealy et al., 2019). This study
excluded participants that already had a diagnosis of diabetes.
Two outcome measures were evaluated (primary and secondary). The initial outcome
looked at the provision of screening for diabetes during routine office visits and specifically
included three variables: fasting glucose, A1C, and lipid profile. Secondary outcome measures
consisted of the prevalence of prediabetes in the current study at hand and patterns of treatment
for prediabetes.
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The results of the survey found that 105,721 office visits, between the years 2012-2015,
were analyzed. From 2012 to 2015, the prevalence of diabetes screening increased from 10% to
13.4%, respectively (Shealy et al.,2019). From these visits, the prevalence of screening was
higher in Black patients 28% (odds ratio [OR], 1.28; 95% CI, 1.03-1.58), and other races 44%
(OR, 1.44; 95% CI, 1.14-1.82) than in Caucasian patients. Screening for patients with a BMI of
25-30 (obese) and greater than or equal 30 were 2.63 times (OR, 3.17; 95% CI, 2.63-3.81) and
2.08 times (OR, 2.08; 95% CI, 1.72-2.51) more prevalent than screening in patients who had a
BMI of <18.5. Patients with known lipid abnormalities or previous prediabetes were 1.69 times
(OR, 1.69; 95% CI, 1.30-2.20) and 2.56 times (OR, 2.56; 95% CI, 2.19-3.00) respectively, more
prevalent to be offered diabetes screening than those who had not. Comparing patients with one
chronic condition to those with greater than 2, the prevalence of screening rose from 56% (OR,
1.56; 95% CI, 1.33-1.83) to 197% (OR, 2.97; 95% CI, 2.37-3.72).
As depicted in the figure below, from Shealy et al., (2019), of all visits that utilized
screening (n=8375), a lipid profile was most commonly ordered (86.6%) followed by A1C
(33.8%) and fasting blood glucose (31.6%).

Figure 3. Prevalence of laboratory testing provided or
ordered for diabetes screening at the visits (n = 8375).
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Figure 3 from “Patterns of diabetes screening and prediabetes treatment during office visits in the
US,” by Shealy, K., Wu, J., Waites, J., Taylor, N., & Sarbacker, G. B. (2019).
As depicted in the figure below, from Shealy et al. (2019), treatment suggestions for
patients found to have prediabetes (n=5,406) was mostly lifestyle management (21.3%, n=1016)
compared to antidiabetic medications (2.9%, n=184). Metformin was the top drug choice of
antidiabetic medications prescribed for prediabetic patients (76.1%, n=140) when compared with
other drug options (Shealy et al.,2019). However, of the 5,406 patients that were found to have
prediabetes, only 2.6% of those patients were prescribed metformin (Shealy et al.,2019).
Unfortunately, greater than 75% of the patients diagnosed with prediabetes in this study were not
provided with either lifestyle modifications or pharmacologic interventions to combat the
progression of prediabetes to overt diabetes.
Figure 4. Treatment provided during visits with prediabetes (n
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Figure 4 from “Patterns of diabetes screening and prediabetes treatment during office visits in the
US,” by Shealy, K., Wu, J., Waites, J., Taylor, N., & Sarbacker, G. B. (2019).
The most prominent strength of this study is the applicability of the data to the general
population in the clinic setting. Limitations include failure to link longitudinal patient visits
together and the lack of details provided to decipher whether the screening test was referred,
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ordered, or provided at the clinic visit. Lastly, random plasma glucose greater or equal to x200
mg/dl was not used in this study. This exclusion could result in a potential selection bias.
Like the previous study, research conducted by Tseng et al. (2017) focused on retrieving
and analyzing survey data where Metformin was prescribed for patients with prediabetes. The
purpose of the study, conducted by Tseng et al., was to discover the prevalence of Metformin
prescriptions in adults within the United States, found to have prediabetes. The research design
and methods of this study first highlight that the data collection took place between the years
2005-2012 and was obtained from the National Health and Nutrition Examination Survey
(NHANES). During the survey, participants took part in an interview, within the comfort of
his/her own home, and additionally visited a mobile examination facility. The survey required
participants to show his/her medication containers to the interviewer and included questions on
prediabetes. Mobile examinations measured vital signs and hemoglobin A1C levels. Tseng et al.
looked to the 2017 American Diabetes Association’s (ADA) guidelines for conducting their study
on the use of metformin in prediabetes. The 2017 ADA guidelines advised consideration of
metformin “in patients with prediabetes and additional risk factors (BMI greater than or equal to
35 kg/m2, age <60 years, or prior gestational diabetes mellitus) or rising hemoglobin A1C
(HBA1c) despite continued adherence to lifestyle intervention”(Tseng et al., 2017). Thus,
participants were selected based on these criteria set forth by the ADA. Twenty-two thousand one
hundred seventy-four adults were screened, and 7,652 subjects were found to have prediabetes
from the criteria as mentioned above. Inclusion criteria included participants with prediabetes
“HbA1c 5.7-6.4%, fasting plasma glucose 100-125 mg/dL, or 2-hour post stimulated plasma
glucose 140-199 mg/dL” (Tseng et al., 2017). Those <20 years of age, people with known/self-
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reported diabetes, pregnant, and participants already on antidiabetic medications (except
Metformin) were excluded from taking part in this study.
Statistical analysis utilized multivariate logistic regression to assess the qualities related
to metformin use in prediabetic patients. Of the 7,652 subjects who were found to have
prediabetes, only a small portion (n=91) were currently taking metformin for prediabetes. The
age-adjusted prevalence of metformin use in prediabetes was 0.7%. Moreover, the age-adjusted
prevalence of metformin use in prediabetes following the criteria of prediabetic hemoglobin A1C
levels was 1.0%. According to the figure below, although the ADA recommends metformin use
in patients with a BMI higher than or equivalent to 35 kg/m2, the data (P=0.19) did not show that
it was statistically significant compared with metformin use in those with a BMI of <35 kg/m2.
However, statistically significant values included patients having a hemoglobin A1C of greater
than or equal to 6% (P= <0.001) and those who were classified as “overweight” by his/her
provider (P=0.001).

Table 2-Adjusted ORs for characteristics associated with metformin use (versus
nonuse of metformin) in prediabetes (n = 7,464)
OR (95% Cl) *

p

HbA1c > 6% (ref. HbA1c < 6%)

4.56 (2.48, 8.37)

< 0.001

Have health insurance (ref. no health insurance)

2.28 (0.85, 6.14)

0.10

History of hypertension (ref. no history of hypertension)

1.22 (0.57, 2.59)

0.61

Identified as overweight by doctor (ref. not identified as
overweight by doctor)

3.27 (1.68, 6.37)

0.001

BMI > 35 kg/m 2 (ref. BMI < 35 kg/m 2 )

1.63 (0. 78, 3.42)

0.19

Characteristic

* Each OR adjusted for additional covariates : HbA 1c > 6%, health insurance status, history of
hypertension, informed of overweight status by doctor, and BMI > 35 kg/m 2 •

Table 2 from Tseng, E., Yeh, H., & Maruthur, N. (2017). Metformin use in prediabetes among
U.S. adults, 2005–2012. Diabetes Care, 40(7), 887–893. http://dx.doi.org/10.2337/dc16-1509
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The limitations of this study include having patients self-report his/her prediabetes status.
It is a possibility that some of the participants had already converted to overt diabetes. However,
to account for this, all the subjects did have at least one lab reading result that categorized them
as “prediabetic” (Tseng et al., 2017).
Efficacy of Lifestyle Modifications Versus Metformin Therapy in Patients with Prediabetes
The Diabetes Prevention Program (DPP) represents the most significant and most
prolonged duration of a randomized controlled clinical trial, conducted between the years 19962001, that compared intensive lifestyle intervention versus masked metformin with the placebo
group. Three thousand one hundred forty-nine subjects were a part of the Diabetes Prevention
Program and were randomly assigned to either 850 mg of metformin twice daily (n = 1073),
masked placebo (n = 1082), or intensive lifestyle intervention (n = 1079). The intensive lifestyle
intervention group was responsible for attending a 16-session curriculum that focused on
achieving a goal of 7% weight loss, moderate-intensity exercise for 150 minutes weekly, in
addition to a low-calorie and low-fat diet. All participants were 25 years of age and older and
were considered to have prediabetes (elevated fasting plasma glucose and impaired glucose
tolerance ranging from 5.3-6.9 mmol/l). Of the total participants, 45% were from racial or ethnic
minority groups, 68% of participants consisted of women (350 of these women had a previous
history of gestational diabetes), and 20% of participants were greater than or equal to 60 years of
age. If a participant had a fasting plasma glucose of greater than or equal to 7.8 mmol/l, this
disqualified participants in the study and the subjects were referred to his/her personal medical
provider. During the 2.8 years of follow-up visits that were studied, researchers found that the
progression of prediabetes converting to overt diabetes was reduced by 58% (95% CI=48%,

METFORMIN IN PREDIABETES

13

66%) and 31% (95% CI=17%, 43%) in the intensive lifestyle intervention and metformin groups,
respectively when compared with placebo.
Following the DPP study, a continuation study named the Diabetes Prevention Program
Outcomes Study (DPPOS), consisting of approximately 88% of the participants that were
initially enrolled in the DPP study (n=2776). As depicted in figure 2 below, after 15 years of
follow-up, it was found that the above-mentioned lifestyle interventions decreased the incidence
of prediabetes conversion to diabetes by 27% (p<0.0001). Although not as efficacious as lifestyle
interventions, metformin reduced the incidence of prediabetes conversion to diabetes by 18%
(p=0.001) and provided information on the long-term effects of utilizing metformin in
prediabetes (DPPOS, 2015).
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Figure 2. from Long-term effects of lifestyle intervention or metformin on diabetes development
and microvascular complications over 15-year follow-up: The Diabetes Prevention Program
Outcomes Study. (2015). The Lancet Diabetes & Endocrinology, 3(11), 866–875.
http://dx.doi.org/0.1016/s2213-8587(15)00291-0
Aroda et al. (2017) aimed to dissect the results of the Diabetes Prevention Program (DPP)
and Diabetes Prevention Program Outcomes Study (DPPOS) even further and explicitly focused
on the effects of metformin within subgroups and what subgroups might benefit the most from
its use.
The results of the study found that Metformin reduced the conversion of patients with
prediabetes to diabetes by 31% when compared to patients that were given a placebo. It also
became evident that the use of metformin proves to have a more significant effect in some
patient populations than others. Participants with a BMI greater than or equal to 35 kg/m2 were
more susceptible to metformin (53% reduction in progression to diabetes) when compared to
placebo outcomes. However, non-obese subjects (with a BMI of 22-29 kg/m2) only had a 3%
reduction in progression to diabetes while taking metformin compared to placebo. Lastly,
participants with an increased fasting glucose level (ranging from 6.1-6.9 mmol/l) had more
significant benefits from Metformin (48% risk reduction) than those with lower fasting glucose
levels (5.3-6.1 mmol/l) (15% risk reduction). The table below depicts that Metformin was
statistically significant (p=0.05) compared with placebo in numerous categories (especially the
number of diabetes cases, fasting plasma glucose, and HbA1c) (Aroda et al., 2017).

METFORMIN IN PREDIABETES

Tab le 2

15

Effect of metfonnin o n diabetes risk a nd CVD ri s k factors a t baseline and at the e nd of each phase of the OPP and DPPOS
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D.:1t.:1 s h own as m eans. unless oth erw ise ind icated
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Table 2 from Aroda, V., Knowler, W., Crandall, J., Perreault, L., Edelstein, S., Jeffries, S.,
…Nathan, D. M. (2017). Metformin for diabetes prevention: Insights gained from the Diabetes
Prevention Program/Diabetes Prevention Program Outcomes. http://dx.doi.org/10.1007.s00125017-4361-9
Several additional studies, consisting of primarily randomized controlled trials, have
explored the possible role of metformin versus lifestyle intervention in patients with prediabetes
and will be outlined briefly below. In comparison with the DPP and DPPOS, the following
studies consist of smaller sample sizes, take place over a shorter duration of time, and most were
conducted outside of the United States.
An older study, conducted prior to the DPP and DPPOS, took place in China by Li et al.
(1999). The goal of this study by Li et al. (1999) was to evaluate the effects of metformin on the
progression of prediabetes to diabetes, glucose metabolism, and insulin sensitivity in subjects
with impaired glucose tolerance (IGT).
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This was a randomized controlled trial that included 90 participants with impaired 75-g
oral glucose tolerance OGTT. Those 90 subjects were screened from 29,938 industrial
corporation employees located in Beijing, China. Two study groups were identified and were
double-blinded for one year: Metformin 250 mg three times daily (for a total of 750 mg) or a
placebo group. Both groups were given primary education on a healthy lifestyle (diet and
exercise) and information on diabetes.
Inclusion criteria contained people with IGT on two separate occurrences. Participants
could be men or women ages 30-60 years of age. Exclusion criteria involved people who have
previously used metformin/are currently taking metformin or those with other diseases (such as
renal hepatic or cardiac diseases).
Of the 90 participants, 70 remained after the study was completed (as 20 participants
were lost due to compliance issues with taking either metformin or placebo). Thirty-three
subjects remained in the metformin group, and 28 (84%) were able to revert to a level of normal
glucose tolerance. At the end of the study, 16.2% of subjects from the placebo group versus 3.0%
of participants from the metformin group (P=0.011) converted to overt diabetes. Of participants
in the metformin group, 84.9% became normoglycemic in comparison to only 51.4% in the
placebo group.
Limitations of this study by Li et al., include applicability to other races and cultures (as
this study consisted solely of Chinese participants). Another limitation is that the fasting glucose
level, in participants within the placebo group, was higher than the metformin group and may be
considered as already having a diagnosis of diabetes. Due to the small sample size, the quality
and validity of this study may not be able to apply to the general population.
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Efficacy of Lifestyle Modifications, in Addition to Metformin, in Prediabetes
Each of the following studies included separate metformin versus lifestyle intervention
groups, like the above studies, but uniquely included a group where metformin, in addition to
lifestyle modifications, was studied. Each study highlights different population groups and has
somewhat different experimental methods.
Ramchandran et al. (2006) included 531 Asian Indian subjects with impaired glucose
tolerance (IGT) in a randomized controlled trial. This study differed from the DPP in two main
ways: lifestyle modifications and the initiation of metformin in prediabetic patients, with
impaired IGT, were evaluated separately and in combination with each other and secondly, the
metformin group was given a lower dosage of metformin (250mg-500mg twice daily) in
comparison to 850 mg twice daily in the DPP study. The primary purpose of this study was to
further evaluate the Asian Indian population as this is a group of people who often have high
impaired glucose tolerance levels but are rarely studied subjects and only accounted for 4.4% of
subjects in the DPP study (Ramachandran et al., 2006).
This study randomized 531 participants (age 33-55) into one of four groups: control,
lifestyle modifications, metformin, or lifestyle modifications in addition to metformin
(Ramachandran et al., 2006). The lifestyle modification group was given education on diet and
physical activity. If the participant was placed in a group that involved physical activity, he/she
did not have to increase his/her physical activity if they were already involved with a laborintensive occupation or if he/she already walked or participated in cycling for greater than 30
minutes per day (Ramachandran et al., 2006).
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After 2 years of follow-up, it was found that the progression of prediabetes to overt
diabetes was reduced by 28.5% (95% CI=20.5, 37.3, p=0.018) in the lifestyle modification-only
group, 28.2% (CI 95% CI=20.3, 37.0, p=0.022) in the lifestyle modification plus metformin
group, and 26.4% (95% CI=19.1, 35.1, p=0.029) in the metformin-only group when compared
with the controlled placebo group (Ramachandran et al., 2006). This shows that lifestyle
modification and metformin separately considerably reduced the progression of prediabetes into
diabetes. However, it also demonstrated that there was no additional benefit when metformin was
combined with lifestyle modifications.
The purpose of the study conducted by Weber et al. (2016) was to evaluate the
effectiveness of expert guidelines on diabetes prevention, through initiating lifestyle
interventions in addition to metformin in patients with prediabetes. The Diabetes Community
Lifestyle Improvement Program (D-Clip) was a controlled, randomized, and translation research
trial comprised of 578 overweight (BMI of 23 to <27.5 kg/m2) and obese (BMI greater than or
equal 27.5 kg/m2) Asian Indian adults. Participants were 20-65 years in age and had prediabetes
with a fasting plasma glucose [FPG] between 5.6-6.9 mmol/L and/or impaired glucose tolerance
(IGT) 2-hour post-load glucose between 7.8 and 11.0 mmol/L. Participants were randomly
placed into two groups: receiving lifestyle advice versus receiving the United States Diabetes
Prevention program research-based lifestyle curriculum in addition to metformin in a stepwise
approach. The metformin group was given 500 mg of metformin twice daily. Exclusion criteria
included pregnancy, breastfeeding mothers, or health diseases or conditions that may have
hindered the ability of the participant to take part in a lifestyle change program. Nineteen
thousand three hundred seventy-seven community members were screened for eligibility.
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The results showed that 34.9% of the control group (that received only lifestyle advice)
versus 25.7% of the participants that received the U.S. Diabetes Prevention Program lifestyle
curriculum plus metformin developed overt diabetes during the three years of follow up
(P=0.014). The relative risk reduction of the intervention group was 32% (95% CI 7-50).
Limitations include ethnically homogenous samples and physical activity delineations.
This was one of the first trials to test the new ADA guidelines in prescribing metformin to
prediabetic patients and was the only study found that focused on the stepwise approach of
adding metformin in patients that were at the highest risk of developing overt diabetes.
The goal of the study, conducted by Malin et al. (2012), was to assess the combined
effects of exercise training and metformin in patients considered to have prediabetes. The
research design and methods begin by describing participant characteristics. Thirty-two
individuals were recruited for this double-blind study and randomly placed into one of four
groups: metformin, placebo, exercising training plus placebo, or exercise plus metformin group.
Subjects were included in this study if they had impaired glucose tolerance. Participants who
were excluded from participating in the study included: smokers, those with recent weight
fluctuations, and those with chronic diseases (Malin et al., 2012).
Subjects in the exercise group took part in three weekly structured 60-75 minutes
sessions. The metformin group received gradually increased doses of metformin, to reduce
adverse gastrointestinal side effects, until the dose reached 2,000 mg daily. Participants were also
instructed to take the medication (either metformin or placebo) with food to further help decrease
gastrointestinal side effects. Both metformin and placebo groups had greater than 90%
compliance (Malin et al., 2012). Insulin sensitivity was measured before and after the 12-week
study was complete.
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At the completion of this study, fasting plasma glucose levels, among the four abovementioned treatment groups did not differ. However, serum insulin levels revealed that the
placebo group increased while the other three treatment groups showed evidence of decreased
serum insulin levels. The results show that metformin, exercise plus placebo, and exercise plus
metformin all enhanced insulin sensitivity when compared to baseline levels (P <0.05).
Safety and Tolerability of Metformin in Prediabetic Patients
Since the Diabetes Prevention Program study was the most extensive study and included
the most abundant population size of studying the effects of metformin in patients with
prediabetes, it consists of the most reliable data on the safety of metformin in prediabetic
patients. Thus, the following articles utilize data from the DPP to evaluate the safety and
tolerability of metformin in prediabetic patients.
In a study conducted by the Diabetes Prevention Program Research Group, consisting of
a randomized, double-blind trial of metformin versus placebo, data was extrapolated from the
Diabetes Prevention Program (DPP) Outcomes Study with study details that have been described
at length above. This randomized, double-blind clinical trial conducted by the Diabetes
Prevention Program (DPP) Research Group (2012) focused on the long-term tolerability and
safety of Metformin use in patients with prediabetes. The DPP Research Group did not uncover
any detrimental side effects or reports of lactic acidosis. They did, however, discover that
gastrointestinal (GI) symptoms were among the most prevalent symptoms reported among
patients receiving Metformin versus those taking placebo (9.5% versus 1.1 %, P < 0.001),
respectively. Nonetheless, reported GI symptoms showed a downward trend throughout the
duration of the DPP study as referenced by the figure below:
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Figure 3—Self-reported gastrointestinal (GI) problems
Figure 3A from Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in
the Diabetes Prevention Program Outcomes Study. (2012). Diabetes Care, 35(4), 731-737.
http://dx.doi.org/10.2337/dc11-1299
In another study, which also evaluated data from the DPP/DPPOS study, the long-term
use of metformin and its relationship with vitamin B12 deficiency was studied (Aroda et al.,
2016). The experimental design of the DPP/DPPOS study is described above. Specifically, the
outcome measures looked at whether or not metformin was associated with B12 deficiency,
peripheral neuropathy, and/or anemia (Aroda et al., 2016).
The results of the analysis found that the metformin participants had low vitamin B12
more often than participants in the placebo group at year five (4.2 versus 2.3; P=.02) but were
not significant at year thirteen (7.4 versus 5.4% ; P=.12) (Aroda et al., 2016). Long-term
metformin use was found to have an increased risk of vitamin B12 deficiency beginning at year
thirteen and increased the risk of vitamin B12 deficiency by 13% per year of metformin use
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(Aroda et al., 2016). In addition, the prevalence of anemia was higher with the use of metformin
but did not significantly differ whether the patient’s B12 level was high, low, or within normal
limits (Aroda et al., 2016). Lastly, when patients had low B12 levels, it was found that the
prevalence of neuropathy was increased (Aroda et al., 2016).
Discussion
Decades of evidence-based research suggests that metformin is an effective, safe, and
tolerable treatment option to prevent or delay diabetes in patients with prediabetes. Lifestyle
modification, in the form of diet and exercise, are currently first-line treatment options to combat
prediabetes; however, metformin is rarely prescribed to patients who may benefit from its use.
Patterns of Diabetes Screening and the Prevalence of Metformin Use for Prediabetes
Shealy et al. (2019) analyzed data from 105,721 office visits and revealed that the
majority of primary care providers are prescribing lifestyle modifications for patients found to
have prediabetes (21.3%, n=1016). However, only 2.6% of patients with prediabetes were
prescribed metformin (n=140). While lifestyle modifications remain to be the most effective
treatment for patients with prediabetes, it is perplexing that only 2.6% of the 105,721 office visits
were prescribed metformin when metformin is currently listed as a grade “A” recommendation
within the prediabetes treatment guidelines set forth by the American Diabetes Association.
It is unclear why primary care providers are not utilizing metformin for prediabetes more
often. Perhaps the provider is unaware that metformin can and, in some circumstances, is
recommended (i.e., in high-risk individuals and patients who refuse/are unable to try lifestyle
modifications, or do not have adequate results with lifestyle modifications alone). Other
providers may not want to prescribe metformin for patients with prediabetes, given that it has not
been officially approved by the FDA for this purpose. The primary care provider should first
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educate the patient on lifestyle modifications and begin having a discussion about metformin
should lifestyle modifications fail or in certain high-risk individuals who may benefit from its
use. The patient should be made aware and educated regarding all of the options for diabetes
prevention and a decision should be made after ***.
With a more narrow focus, Tseng et al. (2017), specifically conducted a study that
analyzed metformin prescription prevalence as suggested by the American Diabetes
Association’s guidelines that include: “patients with prediabetes and additional risk factors (BMI
greater than or equal to 35 kg/m2, age <60 years, or prior gestational diabetes mellitus) or rising
hemoglobin A1C despite continued adherence to lifestyle intervention” (Tseng et al., 2017). Of
the 7,652 subjects that had prediabetes and met the above guidelines for metformin use set forth
by the ADA, only a small portion (n=91) were prescribed metformin and the age-adjusted
prevalence of metformin use in prediabetes was 0.7% (Tseng et al., 2017). This again
exemplifies that metformin is not being prescribed to patients that the ADA suggests could
benefit from its use. This is important because diabetes prevention is imperative and not utilizing
metformin, especially in patients with increased risk factors, presents as an overlooked
opportunity for halting prediabetes progression.
Efficacy of Lifestyle Modifications Versus Metformin Therapy in Patients with Prediabetes
The DPP study found that after 2.8 years of follow-up, the progression of prediabetes
converting to diabetes was reduced by 58% (95% CI=48%, 66%) and 31% (95% CI=17%, 43%)
in the lifestyle modifications and metformin groups, respectively when compared to placebo.
Fifteen years later, the DPPOS study discovered that lifestyle interventions decreased the
incidence of prediabetes to diabetes by 27% (p < 0.0001), while metformin reduced the incidence
of diabetes by 18% (p=0.001) (DPPOS, 2015). These results demonstrate that starting patients on
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lifestyle interventions are more efficacious than metformin alone in both short-term and longterm settings. However, metformin was more efficacious than the placebo group and could
alternatively be used in place of lifestyle modifications.
Efficacy of Lifestyle Modifications, in Addition to Metformin, in Prediabetes
As referenced above, lifestyle modifications have been proven to be highly efficacious in
preventing prediabetes. However, there were few studies that examined the combined effects of
lifestyle modifications plus metformin. These studies revealed that the combined effects of
lifestyle modification in conjunction with metformin use did not provide additional benefits as
one would expect. Specifically, Ramachandran et al. (2006) found that after 2 years of following
up with 531 patients, the progression of prediabetes to overt diabetes was not reduced more in
patients who were in the lifestyle modification plus metformin group 28.2% (95% CI=20.3, 37.0,
p=0.022) versus those in the lifestyle modification-only group 28.5% (95% CI=20.5, 37.3,
p=0.018. The metformin-only group had the lowest reduction to overt diabetes at 26.4% (95%
CI=19.1, 35.1, p=0.029 (Ramachandran et al., 2006).
Unlike the study above, Malin et al. (2012) utilized a much smaller sample size of 32
participants. However, they, too found that metformin added to lifestyle modifications (in the
form of exercise) did not differ significantly from the use of lifestyle modifications or the use of
metformin alone. The most substantial finding in this study, which is not detailed in any other
study to date, is the relatively unchanged level of insulin sensitivity when both metformin and
exercise were combined Ra – 11.08 increased to 11.42 (Malin et al., 2012). Malin et al. (2012)
proposed that metformin could possibly be blunting the effects of exercise training. However,
more research is needed to confirm this hypothesis and whether or not metformin has effects that
may discourage its use when combined with lifestyle modifications.
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Safety and Tolerability of Metformin in Prediabetic Patients
While metformin has been proven to be effective and safe in patients with prediabetes,
research from the DPP (2012) has shown that gastrointestinal side effects, from metformin, tend
to be the most significant side effect when compared to placebo (9.5 % versus 1.1 %, P < 0.001).
Nevertheless, gastrointestinal side effects diminished over the span of the DPP study (DPP,
2012). This demonstrates that patients may initially suffer gastrointestinal side effects but that
they will likely subside after time. Aroda et al. (2016) found less common symptoms, attributed
to metformin use, to include: anemia and vitamin B12 deficiency (which may further provoke
peripheral neuropathy). Thus, the provider should consider ordering laboratory tests to evaluate
for vitamin B12 deficiency and anemia in patients utilizing metformin for diabetes prevention.
The patient and primary care provider should weigh the risks (GI upset, anemia, and
vitamin B12 deficiency which can further elicit peripheral neuropathy) versus the benefits
(decreasing the risk of diabetes) and should evaluate whether these side effects will prevent the
patient from taking metformin. If the latter is the case, a different treatment option should be
utilized to optimize diabetes prevention.
Conclusions
The literature provides evidence that lifestyle modifications should continue to be the
first-line treatment for patients with prediabetes in the primary care setting. However, if lifestyle
modifications fail or if the patient has other high-risk factors, then, metformin should be
considered and initiated as it has been proven to be beneficial when compared to placebo.
Further research needs to be performed regarding the combined use of metformin and lifestyle
modifications as not enough research has been completed thus far and results are puzzling.
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Applicability to Clinical Practice
The goal of this literature review was to evaluate the efficacy of initiating metformin in
patients with prediabetes. The primary care setting is an imperative setting that can be utilized to
improve both the detection and the treatment of prediabetes. However, clear-cut guidelines for
prediabetes treatment are often unclear to the primary care provider, and patients often go
untreated or are not prescribed the correct treatment options for prediabetes. This literature
review aims to further educate the primary care provider in making the proper treatment
decisions in patients with prediabetes, to advocate for patient-centered care.
Decades of evidence-based research suggest that metformin is an effective, safe, and
tolerable treatment option to prevent or delay diabetes in patients with prediabetes. The use of
Metformin has proven its effectiveness in higher-risk patient populations. Even though
metformin has been thoroughly studied in the prediabetes patient population, studies show that it
is not being prescribed to patients who may benefit from its use. First-line treatment of
prediabetes remains to indicate that lifestyle interventions are more effective than metformin.
However, metformin should be considered in high-risk patients, and ADA guidelines should be
utilized.
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